Close but no cigar for Crestor in head-to-head Lipitor study
This article was originally published in Scrip
Executive Summary
AstraZeneca's hopes of shoring up its market share of its statin Crestor (rosuvastatin) against the onslaught of generic Lipitor have been dealt a blow with the top-line data from the SATURN study. Shares in the UK-based firm dropped by more than 3% in early trading in London on 2 September 2.